Does the media favor MDXH or APRE?

In the previous week, Aprea Therapeutics had 1 more articles in the media than MDxHealth. MarketBeat recorded 2 mentions for Aprea Therapeutics and 1 mentions for MDxHealth. Aprea Therapeutics' average media sentiment score of 0.06 beat MDxHealth's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, RADX or APRE?

Aprea Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 16.54 -$24.83M N/A N/A Aprea Therapeutics $290K 35.00 -$12.60M -$1.08 N/A

Does the media prefer RADX or APRE?

In the previous week, Aprea Therapeutics had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Aprea Therapeutics and 1 mentions for Radiopharm Theranostics. Aprea Therapeutics' average media sentiment score of 0.06 beat Radiopharm Theranostics' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer QNCX or APRE?

In the previous week, Quince Therapeutics had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 5 mentions for Quince Therapeutics and 2 mentions for Aprea Therapeutics. Quince Therapeutics' average media sentiment score of 0.79 beat Aprea Therapeutics' score of 0.06 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KYNB or APRE?

In the previous week, Kyntra Bio had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 5 mentions for Kyntra Bio and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.06 beat Kyntra Bio's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aprea Therapeutics (APRE) Competitors

$0.81 -0.01 (-1.67%)

As of 09/3/2026 04:00 PM Eastern

Compare

APRE vs. MDXH, RADX, QNCX, ATNM, and KYNB

Should you buy Aprea Therapeutics stock or one of its competitors? Aprea Therapeutics's main competitors and comparable companies include MDxHealth (MDXH), Radiopharm Theranostics (RADX), Quince Therapeutics (QNCX), Actinium Pharmaceuticals (ATNM), and Kyntra Bio (KYNB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aprea Therapeutics compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

MDxHealth has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Aprea Therapeutics has lower revenue, but higher earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.33	-$33.52M	-$0.72	N/A
Aprea Therapeutics	$290K	35.00	-$12.60M	-$1.08	N/A

34.2% of Aprea Therapeutics shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Aprea Therapeutics had 1 more articles in the media than MDxHealth. MarketBeat recorded 2 mentions for Aprea Therapeutics and 1 mentions for MDxHealth. Aprea Therapeutics' average media sentiment score of 0.06 beat MDxHealth's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MDxHealth has a net margin of -33.46% compared to Aprea Therapeutics' net margin of -4,405.59%. MDxHealth's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

MDxHealth currently has a consensus target price of $2.17, suggesting a potential upside of 198.36%. Aprea Therapeutics has a consensus target price of $3.07, suggesting a potential upside of 280.34%. Given Aprea Therapeutics' higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Aprea Therapeutics beats MDxHealth on 8 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to Radiopharm Theranostics?

Radiopharm Theranostics (NASDAQ:RADX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Radiopharm Theranostics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Aprea Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	16.54	-$24.83M	N/A	N/A
Aprea Therapeutics	$290K	35.00	-$12.60M	-$1.08	N/A

Radiopharm Theranostics currently has a consensus price target of $11.00, suggesting a potential upside of 411.63%. Aprea Therapeutics has a consensus price target of $3.07, suggesting a potential upside of 280.34%. Given Radiopharm Theranostics' higher possible upside, analysts clearly believe Radiopharm Theranostics is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Aprea Therapeutics had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Aprea Therapeutics and 1 mentions for Radiopharm Theranostics. Aprea Therapeutics' average media sentiment score of 0.06 beat Radiopharm Theranostics' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

34.2% of Aprea Therapeutics shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Radiopharm Theranostics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Radiopharm Theranostics' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

Summary

Aprea Therapeutics beats Radiopharm Theranostics on 9 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Quince Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

Aprea Therapeutics has higher revenue and earnings than Quince Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Aprea Therapeutics	$290K	35.00	-$12.60M	-$1.08	N/A

In the previous week, Quince Therapeutics had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 5 mentions for Quince Therapeutics and 2 mentions for Aprea Therapeutics. Quince Therapeutics' average media sentiment score of 0.79 beat Aprea Therapeutics' score of 0.06 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aprea Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quince Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Quince Therapeutics' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 5.6% of Quince Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Quince Therapeutics presently has a consensus target price of $260.00, suggesting a potential upside of 751.06%. Aprea Therapeutics has a consensus target price of $3.07, suggesting a potential upside of 280.34%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Quince Therapeutics is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Quince Therapeutics beats Aprea Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Aprea Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.94	-$48.82M	$0.36	2.92
Aprea Therapeutics	$290K	35.00	-$12.60M	-$1.08	N/A

Actinium Pharmaceuticals has a beta of 0.05, suggesting that its stock price is 95% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

Actinium Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 376.19%. Aprea Therapeutics has a consensus price target of $3.07, suggesting a potential upside of 280.34%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Aprea Therapeutics had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Aprea Therapeutics and 0 mentions for Actinium Pharmaceuticals. Aprea Therapeutics' average media sentiment score of 0.06 beat Actinium Pharmaceuticals' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Aprea Therapeutics	Neutral

Actinium Pharmaceuticals has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Aprea Therapeutics beats Actinium Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Aprea Therapeutics compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Kyntra Bio presently has a consensus target price of $36.00, suggesting a potential upside of 324.03%. Aprea Therapeutics has a consensus target price of $3.07, suggesting a potential upside of 280.34%. Given Kyntra Bio's higher possible upside, equities research analysts clearly believe Kyntra Bio is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Kyntra Bio had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 5 mentions for Kyntra Bio and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.06 beat Kyntra Bio's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyntra Bio has a net margin of 2,199.13% compared to Aprea Therapeutics' net margin of -4,405.59%. Kyntra Bio's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

Kyntra Bio has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

Kyntra Bio has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	5.34	$183.45M	$45.30	0.19
Aprea Therapeutics	$290K	35.00	-$12.60M	-$1.08	N/A

Summary

Kyntra Bio beats Aprea Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APRE vs. The Competition

Export

Metric	Aprea Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.32M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.75	12.66	273.29	25.38
Price / Sales	35.00	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.26	16.29	12.89	6.14
Net Income	-$12.60M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-3.85%	0.34%	0.60%	-0.27%
1 Month Performance	34.54%	8.52%	5.73%	0.68%
1 Year Performance	-46.25%	52.66%	25.35%	14.84%

Aprea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APRE Aprea Therapeutics	3.1832 of 5 stars	$0.81 -1.7%	$3.07 +280.3%	-47.3%	$10.32M	$290K	N/A	7
MDXH MDxHealth	2.018 of 5 stars	$0.79 +6.4%	$2.17 +174.7%	-79.8%	$36.69M	$107.88M	N/A	300	Gap Up
RADX Radiopharm Theranostics	2.3415 of 5 stars	$2.48 +1.6%	$11.00 +343.5%	-60.9%	$35.28M	$2.35M	N/A	N/A	Gap Down
QNCX Quince Therapeutics	2.7409 of 5 stars	$30.93 -7.6%	$260.00 +740.6%	-90.5%	$34.05M	N/A	N/A	60	News Coverage Gap Up
ATNM Actinium Pharmaceuticals	1.8267 of 5 stars	$1.08 +2.9%	$5.00 +363.0%	-38.6%	$33.96M	$35.09M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APRE) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aprea Therapeutics (APRE) Competitors

APRE vs. MDXH, RADX, QNCX, ATNM, and KYNB

How does Aprea Therapeutics compare to MDxHealth?

Summary

How does Aprea Therapeutics compare to Radiopharm Theranostics?

Summary

How does Aprea Therapeutics compare to Quince Therapeutics?

Summary

How does Aprea Therapeutics compare to Actinium Pharmaceuticals?

Summary

How does Aprea Therapeutics compare to Kyntra Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aprea Therapeutics (APRE) Competitors

APRE vs. MDXH, RADX, QNCX, ATNM, and KYNB

How does Aprea Therapeutics compare to MDxHealth?

Which has more risk & volatility, MDXH or APRE?

Which has preferable earnings & valuation, MDXH or APRE?

Do institutionals and insiders hold more shares of MDXH or APRE?

Does the media favor MDXH or APRE?

Is MDXH or APRE more profitable?

Do analysts recommend MDXH or APRE?

Summary

How does Aprea Therapeutics compare to Radiopharm Theranostics?

Which has more risk & volatility, RADX or APRE?

Which has preferable valuation and earnings, RADX or APRE?

Do analysts rate RADX or APRE?

Does the media prefer RADX or APRE?

Do insiders and institutionals hold more shares of RADX or APRE?

Is RADX or APRE more profitable?

Summary

How does Aprea Therapeutics compare to Quince Therapeutics?

Which has more volatility & risk, QNCX or APRE?

Which has stronger earnings & valuation, QNCX or APRE?

Does the media prefer QNCX or APRE?

Is QNCX or APRE more profitable?

Do insiders & institutionals hold more shares of QNCX or APRE?

Do analysts rate QNCX or APRE?

Summary

How does Aprea Therapeutics compare to Actinium Pharmaceuticals?

Which has better valuation & earnings, ATNM or APRE?

Which has more risk and volatility, ATNM or APRE?

Do analysts rate ATNM or APRE?

Does the media favor ATNM or APRE?

Is ATNM or APRE more profitable?

Do insiders and institutionals hold more shares of ATNM or APRE?

Summary

How does Aprea Therapeutics compare to Kyntra Bio?

Do analysts prefer KYNB or APRE?

Do institutionals & insiders have more ownership in KYNB or APRE?

Does the media prefer KYNB or APRE?

Is KYNB or APRE more profitable?

Which has more risk and volatility, KYNB or APRE?

Which has higher earnings & valuation, KYNB or APRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools